We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+19.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
+$244M
Cap. Flow
+$74.7M
Cap. Flow %
4.68%
Top 10 Hldgs %
27.52%
Holding
150
New
14
Increased
55
Reduced
10
Closed
13

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$36M
2
AMRN
Amarin Corp
AMRN
+$13.9M
3
TSRO
TESARO, Inc.
TSRO
+$13.7M
4
DHR icon
Danaher
DHR
+$12.8M
5
PTHN
Patheon N.V.
PTHN
+$11M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
2
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$18M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.8M
4
MD icon
Pediatrix Medical
MD
+$9.92M
5
XNPT
XENOPORT, INC.
XNPT
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 81.88%
2 Financials 3.67%
3 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
101
Innoviva
INVA
$1.48B
$3.7M 0.23%
336,900
– –
PRGO icon
102
Perrigo
PRGO
$1.78B
$3.5M 0.22%
37,900
– –
SYRE icon
103
Spyre Therapeutics
SYRE
$9.25B
$3.36M 0.21%
20,964
– –
MD icon
104
Pediatrix Medical
MD
$2.2B
$3.31M 0.21%
50,000
-145,000
-74% -$9.92M
NBRV
105
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3M 0.19%
1,704
– –
STE icon
106
Steris
STE
$23.1B
$2.92M 0.18%
40,000
– –
ITCI
107
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.9M 0.18%
190,000
– –
CDTX
108
DELISTED
Cidara Therapeutics
CDTX
$2.86M 0.18%
12,500
– –
ASMB icon
109
Assembly Biosciences
ASMB
$529M
$2.81M 0.18%
32,500
– –
MCRB icon
110
Seres Therapeutics
MCRB
$48.9M
$2.7M 0.17%
11,000
-2,100
-16% -$737K
DBVT
111
DBV Technologies
DBVT
$847M
$2.65M 0.17%
7,300
– –
TTPH
112
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.54M 0.16%
33,125
+11,875
+56% +$951K
GNCA
113
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.46M 0.15%
60,000
– –
SCYX icon
114
SCYNEXIS
SCYX
$52M
$2.46M 0.15%
7,938
– –
EGLT
115
DELISTED
Egalet Corporation
EGLT
$2.28M 0.14%
300,000
– –
GBT
116
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.26M 0.14%
98,000
– –
AMSG
117
DELISTED
Amsurg Corp
AMSG
$2.18M 0.14%
+32,500
New +$2.27M
DMTX
118
DELISTED
Dimension Therapeutics, Inc
DMTX
$2.17M 0.14%
271,370
– –
NVCR icon
119
NovoCure
NVCR
$1.91B
$1.83M 0.11%
214,316
– –
NVAX icon
120
Novavax
NVAX
$1.31B
$1.77M 0.11%
42,625
– –
DVAX
121
DELISTED
Dynavax Technologies
DVAX
$1.73M 0.11%
165,000
– –
BHC icon
122
Bausch Health
BHC
$2.34B
$1.68M 0.11%
68,600
+2,500
+4% +$64.7K
EXEL icon
123
Exelixis
EXEL
$13.4B
$1.6M 0.1%
+125,000
New +$1.35M
CHMA
124
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.45M 0.09%
492,500
– –
ANTH
125
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.42M 0.09%
56,250
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rock Springs Capital Management held 150 positions worth $1.6B, up 18% from $1.35B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management deployed $74.7M of net new capital in Q3 2016, opening 14 new positions and adding to 55 existing holdings. Its largest new stake was Merck: 615,700 shares worth $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Pediatrix Medical, an estimated $9.92M trimmed.

  • Rock Springs Capital Management's largest Q3 2016 buy was Merck: 615,700 shares worth $36.7M.
  • Rock Springs Capital Management added most to TESARO, Inc. in Q3 2016, an estimated $13.7M increase.
  • Rock Springs Capital Management's biggest Q3 2016 reduction was Pediatrix Medical, cutting an estimated $9.92M.
  • Rock Springs Capital Management fully exited Teva Pharmaceuticals in Q3 2016, selling an estimated $19.8M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.6B portfolio in Q3 2016.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q3 2016.
  • Rock Springs Capital Management's portfolio value rose 18% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.